- Home
- NUVL vs COLB Comparison
NUVL vs COLB Comparison
Compare NUVL & COLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- COLB
- Stock Information
- Founded
- NUVL 2017
- COLB 1993
- Country
- NUVL United States
- COLB United States
- Employees
- NUVL N/A
- COLB N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- COLB Major Banks
- Sector
- NUVL Health Care
- COLB Finance
- Exchange
- NUVL Nasdaq
- COLB Nasdaq
- Market Cap
- NUVL 5.6B
- COLB 5.2B
- IPO Year
- NUVL 2021
- COLB N/A
- Fundamental
- Price
- NUVL $74.61
- COLB $23.38
- Analyst Decision
- NUVL Strong Buy
- COLB Hold
- Analyst Count
- NUVL 8
- COLB 15
- Target Price
- NUVL $115.50
- COLB $29.33
- AVG Volume (30 Days)
- NUVL 548.5K
- COLB 1.9M
- Earning Date
- NUVL 05-08-2025
- COLB 07-24-2025
- Dividend Yield
- NUVL N/A
- COLB 6.16%
- EPS Growth
- NUVL N/A
- COLB 1.90
- EPS
- NUVL N/A
- COLB 2.37
- Revenue
- NUVL N/A
- COLB $1,830,830,000.00
- Revenue This Year
- NUVL N/A
- COLB $17.74
- Revenue Next Year
- NUVL N/A
- COLB $31.25
- P/E Ratio
- NUVL N/A
- COLB $9.87
- Revenue Growth
- NUVL N/A
- COLB N/A
- 52 Week Low
- NUVL $55.54
- COLB $18.20
- 52 Week High
- NUVL $113.51
- COLB $32.85
- Technical
- Relative Strength Index (RSI)
- NUVL 54.31
- COLB 45.02
- Support Level
- NUVL $70.25
- COLB $23.17
- Resistance Level
- NUVL $75.97
- COLB $24.28
- Average True Range (ATR)
- NUVL 3.09
- COLB 0.55
- MACD
- NUVL 0.13
- COLB -0.14
- Stochastic Oscillator
- NUVL 79.92
- COLB 7.87
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About COLB Columbia Banking System Inc.
Columbia Banking System Inc is a registered bank holding company whose wholly-owned banking subsidiary is Columbia State Bank. The company provides a full range of banking services to small and medium sized businesses, professionals, and individuals throughout Washington, Oregon, Idaho, and California. The company's subsidiary Columbia Trust Company is an Oregon trust company that provides agency, fiduciary, and other related trust services with offices in Washington, Oregon, and Idaho. The firm offers various products and services under Personal Banking, Business Banking, and Wealth Management divisions.